Ocugen is accelerating its commercial push as OCU410 moves into Phase 3 with RMAT status, strengthening its lead gene therapy pipeline. The company also outline

Ocugen is accelerating its commercial push as OCU410 moves into Phase 3 with RMAT status, strengthening its lead gene therapy pipeline. The company also outlined a $130 million Q2 2026 financing deal and a binding MENA licensing term sheet for OCU400.